The human estrogen receptor ␣ (ER␣) and the recently identified ER␤ share a high degree of amino acid homology; however, there are significant differences in regions of these receptors that would be expected to influence transcriptional activity. Consequently, we compared the mechanism(s) by which these receptors regulate target gene transcription, and evaluated the cellular consequences of coexpression of both ER subtypes. Previously, it has been determined that ER␣ contains two distinct activation domains, ER␣-AF-1 and ER␣-AF-2, whose transcriptional activity is influenced by cell and promoter context. We determined that ER␤, like ER␣, contains a functional AF-2, however, the ER␤-AF-2 domain functions independently within the receptor. Of additional significance was the finding that ER␤ does not contain a strong AF-1 within its amino-terminus but, rather, contains a repressor domain that when removed, increases the overall transcriptional activity of the receptor. The importance of these findings was revealed when it was determined that ER␤ functions as a transdominant inhibitor of ER␣ transcriptional activity at subsaturating hormone levels and that ER␤ decreases overall cellular sensitivity to estradiol. Additionally, the partial agonist activity of tamoxifen manifest through ER␣ in some contexts was completely abolished upon coexpression of ER␤. In probing the mechanisms underlying ER␤-mediated repression of ER␣ transcriptional activity we have determined that 1) ER␣ and ER␤ can form heterodimers within target cells; and 2) ER␤ interacts with target gene promoters in a ligand-independent manner. Cumulatively, these data indicate that one role of ER␤ is to modulate ER␣ transcriptional activity, and thus the relative expression level of the two isoforms will be a key determinant of cellular responses to agonists and antagonists. (Endocrinology 140: 5566 -5578, 1999) T HE HUMAN ESTROGEN receptor (ER) belongs to the nuclear receptor superfamily of ligand-inducible transcription factors (1), whose members include the receptors for steroids, thyroid hormone, retinoic acid, vitamin D, and orphan receptors for which no ligands have yet been identified. The mechanism of action of ER is similar to that of other nuclear receptors. In the absence of hormone, the receptor is sequestered within the nuclei of target cells in a multiprotein inhibitory complex. The binding of ligand induces an activating conformational change within ER, an event that promotes homodimerization and high affinity binding to specific DNA response elements (EREs) located within the regulatory regions of target genes (2). In addition to the classic ligand-mediated activation pathway, it has been shown that ER can be activated in the absence of ligand by growth factors or other agents that elevate intracellular cAMP levels (3, 4). Although the physiological importance of the ligand-independent signaling pathways remains to be determined, it has been shown in ER knockout mice that the uterotropic responses to both 17␤-estradiol and epidermal growth factor require a functional ER (5). Thus, ER appears to be a key point of convergence of multiple signaling pathways, an observation that complicates our understanding of the pharmacology of estrogens and antiestrogens.
T HE HUMAN ESTROGEN receptor (ER) belongs to the
nuclear receptor superfamily of ligand-inducible transcription factors (1) , whose members include the receptors for steroids, thyroid hormone, retinoic acid, vitamin D, and orphan receptors for which no ligands have yet been identified. The mechanism of action of ER is similar to that of other nuclear receptors. In the absence of hormone, the receptor is sequestered within the nuclei of target cells in a multiprotein inhibitory complex. The binding of ligand induces an activating conformational change within ER, an event that promotes homodimerization and high affinity binding to specific DNA response elements (EREs) located within the regulatory regions of target genes (2) . In addition to the classic ligand-mediated activation pathway, it has been shown that ER can be activated in the absence of ligand by growth factors or other agents that elevate intracellular cAMP levels (3, 4) . Although the physiological importance of the ligand-independent signaling pathways remains to be determined, it has been shown in ER knockout mice that the uterotropic responses to both 17␤-estradiol and epidermal growth factor require a functional ER (5) . Thus, ER appears to be a key point of convergence of multiple signaling pathways, an observation that complicates our understanding of the pharmacology of estrogens and antiestrogens.
Until recently it was considered that a single ER was responsible for all of the biological actions of estrogens and antiestrogens. However, the recent identification of ER␤ (6, 7) has indicated that the cellular responses to ER ligands are far more complex. The two estrogen receptors, ER␣ and ER␤, have similar overall structures, displaying a high degree of amino acid conservation in the central DNA-binding domain (DBD) and moderate conservation in the ligand-binding domain (LBD; C-terminus), but considerable divergence in the amino-terminus. Not surprising, therefore, ER␣ and ER␤ interact with the same DNA response elements (8) and exhibit similar, but not identical, ligand binding characteristics. Although a specific physiological role for ER␤ remains to be defined, its identification has provided a potential explanation for the biological actions of estrogen(s) in cells where no immunoreactive ER␣ could be detected. Interestingly, preliminary localization studies have revealed that there are many tissues in which both ER subtypes are coexpressed (6, 7, 9) . Thus, the impact of ER␤ on estrogen biology is likely to occur as a consequence of 1) direct actions of ER␤, where it is responsible for regulating target gene transcription; and 2) indirect activities, where ER␤ modulates ER␣ action in tissues where they are coexpressed.
Although the precise mechanism by which ER regulates transcription remains to be determined, considerable progress has been made in defining the domains within ER␣ required for its activity. Specifically, it has been demonstrated that the transcriptional activity of ER␣ is mediated by two activation functions (AFs) located in the amino-terminal (AF-1) and carboxyl-terminal (AF-2). Although both of these AFs function in a synergistic manner in most circumstances, they can also function independently in a cell-and promoterspecific manner, an activity that may explain the tissueselective agonist activity of some ER ligands (10, 11) . In this regard, it has been observed that 17␤-estradiol can function as an agonist in all environments regardless of whether AF-1 or AF-2 is the dominant activator. Not surprisingly, therefore, the pure antiestrogen ICI 182,780, which inhibits the activity of both AF-1 and AF-2, completely blocks the ability of ER␣ to activate transcription through classical ERE-mediated pathways. Unlike the pure antiestrogens, however, the relative agonist/antagonist activities of most other antiestrogens are determined by the cell and promoter context. For instance, compounds such as tamoxifen inhibit AF-2 activity, and consequently function as antagonists in all environments where AF-2 is required. In contexts where AF-1 is the dominant activator, on the other hand, tamoxifen manifests partial agonist activity. These observations led to the hypothesis that the tissue-selective biological activity exhibited by selective ER modulators (SERMs) such as tamoxifen, reflects their ability to differentially regulate AF-1 or AF-2. However, the identification of ER ligands such as raloxifene and GW5638, which function as estrogens in the bone and the cardiovascular system but do not appear to function as either AF-1 or AF-2 agonists, indicates that the existing models of ER pharmacology are incomplete (12, 13) . Clearly, they must now be expanded to include a consideration of the impact of ER␤. It is likely that the existence of ER␣ and ER␤ will be as important to ER pharmacology as the two progesterone receptor subtypes, PR-A and PR-B, are to the pharmacology of progestins and antiprogestins. We base this hypothesis on our earlier studies of PR action, where it was shown that PR-A and PR-B were not functionally identical. Specifically, we observed that both receptor forms could manifest autonomous activity in some cell contexts, whereas in others the A isoform was a weak transcriptional activator and, in fact, functioned as a transdominant inhibitor of human PR-B activity (14) . The possibility that there were similarities between these two systems prompted us to explore the impact of ER␤ on the pharmacology of ER␣. Although ER␣/ER␤ are not derived from the same gene as are the two forms of PR, we believed that it would be useful to consider ER␣/ER␤ as having a similar relationship as PR-A/B. The aim of this study, therefore, was to compare the transcriptional activities of ER␣ and ER␤ and to evaluate the contribution of ER␤ to the overall pharmacology of estrogens and antiestrogens. 
Materials and Methods

Plasmids
The mammalian expression plasmid for ER␣ (pRST7ER) has been described previously (11) . Plasmids expressing ER␣ mutants (ER-AF1, ER-AF2, ER-Null) were also described previously (11) . The ER␤ expression plasmid, pRST7ER␤, was constructed as follows. A PCR 3.1 vector (Invitrogen, Carlsbad, CA) containing the human ER␤ coding sequence (amino acids 1-477; gift from Dr. Mark Nuttall, SmithKline Beecham) was digested with HindIII and XbaI, and ER␤ was ligated into pRST7ER, previously digested with HindIII and XbaI to remove the ER␣ complementary DNA (cDNA). An epitope-modified series of ER␣ and ER␤ expression vectors was also created. Specifically, an amino-terminus FLAG tag was added to the ER␣ and ER␤ expression vectors by PCR. The sequences of the oligonucleotides for PCR were 5Ј-GTGGACGTC-GACATGGACTACAAAGACGACGACGACAAAATGACCATGACC-CTCCAC (forward) and 3Ј-GTGGAGGGATCCTCAGACTGTGGCAG-GGAAACC (reverse) for ER␣ and 5Ј-GTGGACGTCGACATGGACTA-CAAAGACGACGACGACAAAATGAATTACAGCATTCCC (forward) and 3Ј-GTGAGGTCTAGATCACTGAGACTGTGGGTT (reverse) for ER␤.
The mammalian expression plasmid for the ER␤ mutant ER␤-AF1 was constructed by site-directed mutagenesis. The pRST7ER␤ plasmid was used as the template, and the three point mutations were created using PCR-based oligonucleotide-directed mutagenesis, according to the manufacturer's protocol (Stratagene, La Jolla, CA). The sequences of the oligonucleotides used for PCR were 5Ј-GTGGTCCCAGTGTATGC-CCTGCTGCTGGCG ATGCTGGCTGCCCACGTGCTTCGCGGG (forward) and 5Ј-CCCGCGAAGCACGTGGGCAGCCAGCATCGCCAG-CAGCAGGGCATACAC TGGGACCAC (reverse).
The plasmid ER␤-AF2 was constructed as follows: an empty pRST7 vector was first created by digesting pRST7ER with HindIII and SmaI to remove the ER␣ cDNA, blunt ends within the vector were created with Klenow, and the vector was recircularized by ligation. The pRST7 vector was digested with XbaI, and a PCR fragment was generated from pRST7ER␤ (containing amino acids 90 -477 of the coding sequence for ER␤) and ligated into the pRST7 vector. The sequences of the oligonucleotides used for PCR were 5Ј-GTGAGGTCTAGAATGAAGAGGGAT-GCTCACTTC (forward) and 3Ј-GTGAGGTCTAGATCACTGAGACT-GTGGGTT (reverse).
To compare the stability of the ER␤ mutants in transfected cells, we created a duplicate set of vectors in which an amino-terminus FLAG tag was added to the expression vectors for the ER␤ mutants by PCR. The sequences of the oligonucleotides used for PCR for the ER␤-AF1 mutant were the same as those used to construct the FLAG-tagged wild-type ER␤. The oligonucleotides used to create the FLAG-tagged ER␤-AF2 mutant were 5Ј-GTGGACTCTAGAATGGACTACAAAGACGACGA-CGACAAATGCGCTGTCTG CAGCGATTAC (forward) and 3Ј-GT-GAGGTCTAGATCACTGAGACTGTGGGTT (reverse).
The GAL4-DBD-ER N-terminus fusion constructs were cloned into the pBK-cytomegalovirus (CMV) mammalian expression vector. Construction of the pBKC-DBD plasmid has been described previously (15) . pBKC-DBD-ER␣-(1-182) was constructed as follows. The pBKC-DBD plasmid was digested with EcoRI and ClaI, and a PCR fragment (containing the coding sequence for the first 182 amino acids of ER␣) was generated from pRST7ER and ligated into these sites. The sequences of the oligonucleotides for PCR were 5Ј-GTGCAGGAATTCATGACCAT-GACCCTCCAC (forward) and 5Ј-GTGCAGATCGATAGTCTCCTTG-GCAGATTC (reverse). pBKC-DBD-ER␤-(1-95) was constructed as follows. The pBKC-DBD plasmid was digested with EcoRI and ClaI, and a PCR fragment (containing the coding sequence for the first 95 amino acids of ER␤) was generated from pRST7ER␤ and ligated into these sites. The sequences of the oligonucleotides for PCR were 5Ј-GTGCAGGAAT-TCATGAATTACAGCATTCCC (forward) and 5Ј-GTGCAGATCGAT-GAAGTGAGCATCCCTCTT (reverse).
pBKC-DBD-ER␣-LBD(3x) was constructed as follows: the pBKC-DBD plasmid was digested with EcoRI and ClaI, and a PCR fragment (containing the coding sequence for amino acids 282-595 of ER␣) was generated from pRST7-ER-AF-1 and ligated into these sites. The sequences of the oligonucleotides for PCR were 5Ј-GTGCAGGAATTCAT-GTCTGCTGGAGACATGAGA (forward) and 3Ј-GTGCAGATCGAT-GACTGTGGCAGGGAAACC (reverse).
All of the PCR-based constructs were sequenced to verify the accuracy of the amplified sequences.
Cell culture and transient transfection assays
HepG2, HeLa, and 293 cells were maintained in MEM (Life Technologies, Inc.) supplemented with 10% FCS (Life Technologies, Inc.). MCF-7 and SKBR3 cells were maintained in DMEM (Life Technologies, Inc.) supplemented with 10% FCS (Life Technologies, Inc.). Cells were plated in 24-well plates (coated with gelatin for transfections of HepG2 cells) 24 h before transfection. DNA was introduced into the cells using lipofectin (Life Technologies, Inc.). Triplicate transfections were performed using 3 g total DNA. In standard transfections, 1500 ng reporter (C3-Luc, 3x-ERE-TATA-Luc, or 5x-GAL4-TATA-Luc), 500 ng receptor (pRST7ER, pRST7ER␤, ER mutants, or GAL4 fusions), 100 ng of the pBKC-␤gal normalization vector (16) , and 900 ng of the control vector pBSII-KS (Stratagene) were used. The reporter C3-Luc contains the estrogen-responsive complement 3 gene promoter, and the 3x-ERE-TATALuc reporter contains three copies of the vitellogenin ERE. The reporter 5x-GAL4-TATA-Luc (a gift from Dr. Xiao-Fan Wang, Duke University Medical Center) contains five palindromic copies of the GAL4 transcription factor response element cloned into pGL2-TATA-Inr (Stratagene). Cells were incubated with the DNA/lipofectin mix for 3 h, then washed with PBS and incubated with the appropriate hormone in phenol red-free medium containing 10% charcoal-stripped FCS (HyClone Laboratories, Inc., Logan, UT) for 48 h. Luciferase and ␤-galactosidase assays were performed as described previously (17) . All experiments were repeated a minimum of three times.
Western immunoblot analysis
293 cells (human embryonic kidney cells) were transfected with the expression plasmids for ER␣, ER␤, or the ER␤ mutants. Whole cell extracts were prepared as described previously (18) . Fifty micrograms of whole cell extracts for each sample were run on a 10% SDS-PAGE gel and transferred to nitrocellulose. Immunoblotting was performed using a mouse monoclonal anti-FLAG antibody. Immunocomplexes were detected by ECL.
Results
The ␣-and ␤-forms of the human ER are functionally distinct
We used a cotransfection assay reconstituted in HepG2 (human hepatoma) or HeLa (human cervical carcinoma) cells to compare the transcriptional activities and ligand responsiveness of ER␣ and ER␤. These cell lines were chosen for our studies because they require exogenous ER␣ or ER␤ to activate ERE-mediated transcription, enabling an assessment of the transcriptional responses of each receptor in isolation. Specifically, the ER expression vectors (pRST7ER and pRST7ER␤) were transiently transfected into either HepG2 or HeLa cells together with the estrogen-responsive reporter 3x-ERE-TATA-Luc or C3-Luc. The input concentration for each expression vector used in these studies was equivalent and was that which gave a maximal response under the conditions of the assay. In addition, using a duplicate set of vectors in which we added an amino-terminus FLAG epitope, we could show by Western immunoblot analysis that the ER␣ and ER␤ cDNAs directed similar levels of ER expression (data not shown). Although we demonstrated that the presence of the FLAG tag did not affect the estradiolmediated transcriptional activity of either receptor (data not shown), we elected to use the native receptors for our studies because we were unsure how the FLAG tag would affect more subtle functions of ER␣ and ER␤. Using this system we examined the transcriptional responses of ER␣ and ER␤ over a range of concentrations of the different ER ligands (Fig. 1A) . Both receptors were activated by 17␤-estradiol, although we observed that ER␣ is a more efficacious activator in this model system. Interestingly, all of the SERMS and pure antagonists tested displayed no agonist or inverse agonist activities on ER␤ on either of the promoters studied ( Fig. 1A and data not shown). As shown previously (16), 4-hydroxytamoxifen displayed partial agonist activity on ER␣ in HepG2 cells on the C3-Luc reporter. In this environment, GW7604 did not exhibit agonist activity on ER␣, whereas ICI 182,780, raloxifene, and idoxifene functioned as inverse agonists.
The initially reported form of the human ER␤ is 477 amino acids in length (ER␤-short), and its expression has been verified in several tissues (7) . However, an isoform that contains an additional 53 amino acids at the N-terminus (ER␤-long) has recently been described, and this form is also detectable in vivo (19) . We characterized the transcriptional activity of the two ER␤ isoforms to determine whether the additional sequences had any impact on the observed responsiveness to estrogens and antiestrogens. However, under the conditions of our assays, the activities of ER␤-short or ER␤-long in response to ER agonists and antagonists were indistinguishable (data not shown). Cumulatively, these results suggest that the responses of ER␣ and ER␤ to pharmacological agents are different, a finding that may be important in understanding the cell-selective actions of these compounds.
We observed that 17␤-estradiol was a stronger activator of ER␣ than ER␤ in HepG2 cells on the C3-Luc reporter (Fig.  1A) . To investigate whether this observation holds in other cell and promoter contexts, we examined the effect of the agonist 17␤-estradiol on ER␣ and ER␤ transcriptional activities in HepG2 and HeLa cells on the 3x-ERE-TATA-Luc and C3-Luc reporters ( Fig. 1, B-D) . In the absence of hormone, ER␣ showed a significantly higher level of basal transcriptional activity than ER␤ in both HepG2 (Fig. 1B ) and HeLa cells (Fig. 1, C and D) . This effect was observed on both the simple and complex promoters. In comparing the overall efficacies of ER␣ and ER␤, the basal activity of the former must be considered, as we have shown previously that this activity is receptor-dependent and can be completely suppressed using pure antiestrogens (16) . It has been reported previously that ER␣ and ER␤ have equivalent affinities for estradiol (8) ; however, in our assays the EC 50 for estradiol was approximately 1.5 orders of magnitude less for ER␣ than for ER␤ in both HepG2 (Fig. 1B) and HeLa (data not shown) cells. Furthermore, the efficacies displayed by ER␣ were consistently higher than those displayed by ER␤ under the conditions we used (Fig. 1, B and C) . Reproducibly, we found that ER␤ demonstrates about 20 -60% of the total activity of ER␣. Similar results were observed in transient transfection assays performed in ROS (rat osteosarcoma) and SKBR3 (mammary carcinoma) cell lines (data not shown). Based on these studies, we conclude that 17␤-estradiol is a more potent and efficacious activator of ER␣, and that it is likely that both receptors contribute in a unique manner to the cellular response to estrogens. Overall, our results define a major mechanistic distinction between the two ERs; ER␤ is strictly dependent on pure agonists for the activation of transcription from its target promoters, whereas ER␣ can be activated by both agonists, partial agonists (SERMS), and ligand-independent mechanisms.
The activation domains within ER␣ and ER␤ are not functionally equivalent
We and others have shown that both activation domains, AF-1 and AF-2, are required for maximal agonist-dependent and ligand-independent activation of transcription by ER␣ (11) . Additionally, in contexts where ER␣-AF-1 alone can function as an autonomous activator we were able to demonstrate that 4-hydroxytamoxifen manifests partial agonist activity. Using similar assays, reconstituted in several cell and promoter backgrounds, we were unable to detect significant ER␤-mediated 4-hydroxytamoxifen agonist activity, suggesting that this receptor isoform may not possess a functional AF-1 or, alternatively, that it may have a different type of activation domain within this region.
To define the mechanism(s) underlying the differential activation profiles of ER␣ and ER␤, we wanted to determine the relative contributions of the N-terminus (AF-1) and Cterminus (AF-2) activation domains to the transcriptional activity of the whole receptors. Previously, our laboratory has created mutations in ER␣ that abolish the activity of AF-1 or AF-2 (11). We have now constructed the corresponding . After 48 h, transcription was quantitated by assaying for luciferase activity, and all transfections were normalized for efficiency using an internal ␤-galactosidase control plasmid (pCMV-␤-gal). Each data point is the average of triplicate measurements of transcriptional activity, and the average coefficient of variation of each value is less than 10%. B, HepG2 cells and HeLa cells (C and D) were transfected with the ER␣ or ER␤ expression plasmids and the 3x-ERE-TATA-Luc or C3-Luc reporter. Cells were induced with 17␤-estradiol (E2) for 48 h, and luciferase assays were performed. Each value was normalized to the ␤-galactosidase activity. Each data point is the average of triplicate determinations, and the average coefficient of variance for each value is less than 10%. mutations in ER␤ ( Fig. 2A) , and this has enabled us to assess the relative contributions of each AF to the transcriptional activities of ER␣ and ER␤. To compare the activities of our mutants, HepG2 cells and HeLa cells were transiently transfected with wild-type ER␣ or ER␤ or the mutant receptor to be tested together with the C3-Luc reporter. Because of the difficulty in obtaining antibodies that can be used to measure the relative expression of ER␣ and ER␤, we elected to per-
The activation domains within ER␣ and ER␤ are not functionally equivalent. A, The ER␣ activation domain mutants were created, as described previously (37). The ER␤-AF1 construct was made by introducing three amino acid changes into the AF2 region of the receptor, substituting alanine for amino acids located at positions 436, 440, and 443. The ER␤-AF2 construct was made by deleting the N-terminus (amino acids 1-95) of the wild-type receptor. B, HepG2 cells and HeLa cells were transiently transfected with the ER␣ wild-type or mutant receptors together with the C3-Luc reporter. After transfection, cells were treated with vehicle (nh) or increasing concentrations (ranging from 1 pM to 1 M) of 17␤-estradiol (E2). After 48 h, cells were harvested and assayed for luciferase activity, and all transfections were normalized for efficiency using the internal pCMV-␤-gal control plasmid. Each data point is the average of triplicate determinations, and the average coefficient of variance for each value is less than 10%. C, HepG2 cells and HeLa cells were transiently transfected with the ER␤ wild-type or mutant receptor together with the C3-Luc reporter and the pCMV-␤-gal control vector. Cells were induced with 17␤-estradiol (E2) for 48 h, and luciferase assays were performed. Each value was normalized to the ␤-galactosidase activity. Each data point is the average of triplicate determinations, and the average coefficient of variance for each value is less than 10%.
form all of our studies at input plasmid concentrations that yield the maximal activity in a given assay. Consequently, our studies do not allow us to compare ER␣ and ER␤ on a molecule:molecule basis, but, rather, permit us to compare these receptors at a functional level. We have successfully used this approach in the past to compare the transcriptional activities of a series of ER␣ mutants (11) . The results of this analysis are shown in Fig. 2 . As expected, ER␣ displays a dose-dependent increase in activity in the presence of 17␤-estradiol in both HepG2 and HeLa cells (Fig. 2B ). In addition, as shown before (37), mutants containing AF-1 or AF-2 alone are also capable of activating transcription, although their activities are influenced by both the cell and promoter context in which they were assayed. In HepG2 cells, for instance, ER␣-AF-1 is significantly more active than ER␣-AF-2; thus, in this environment AF-1 appears to be the dominant activator. In HeLa cells, however, both ER␣-AF-1 and ER␣-AF-2 display identical activation profiles, and their combined activity is significantly less than that of the intact receptor throughout the entire range of hormone concentrations. Interestingly, in both cell contexts, ER␣-AF-1 and ER␣-AF-2 exhibit significantly lower ligand-independent activity compared with the intact ER␣. These studies confirm our previous findings that both AF-1 and AF-2 contribute to the overall transcriptional activity of ER␣, and that the relative activity of each activation domain is dependent on the cell context.
We next examined the activities of ER␤ and the ER␤ AF mutants in HepG2 and HeLa cells (Fig. 2C) . To find suitable dose ranges of input plasmids for our studies, we created a duplicate set of vectors in which the amino-termini of the mutant receptors were modified by the addition of a FLAG tag. Using these expression vectors we were able to demonstrate that ER␤ and ER␤-AF-1 were expressed equivalently, whereas ER␤-AF-2 expression was elevated by about 50%. With this information in hand, we proceeded with the evaluation of the transcriptional activity of the untagged, native ER␤ mutants. Because our vectors produce equivalent amounts of receptor, we performed all of our studies at equivalent input plasmid concentrations, selecting that which gave a maximal response under the conditions of the assay for all receptors. As seen with ER␣, the wild-type ER␤ is a ligand-dependent transcriptional activator in both cell lines. However, although ER␣-AF-1 can function autonomously in some cell types, ER␤-AF-1 is transcriptionally inactive in both HepG2 and HeLa cells. Overall, the most surprising finding was that removal of the amino-terminus (ER␤-AF-2) enhances ER␤ transcriptional activity rather than decreases it as was seen with ER␣. Of additional importance was the finding that ER␤-AF-2 is extremely active in environments where ER␣-AF-2 is essentially transcriptionally inactive. Therefore, we conclude that the C-terminus (AF-2) mediates the transcriptional activity of ER␤ in response to 17␤-estradiol, and that this domain functions independently of the amino-terminus. Furthermore, sequences within the N-terminus have a negative impact on the overall transcriptional activity of ER␤, and their removal creates a mutant whose function is similar, but not identical, to that of ER␣. It is possible that ER␤ does, in fact, contain a functional AF-1 domain and that it may be functional in contexts not represented by our assays. These studies clearly indicate that the activation domains of ER␣ and ER␤ are not identical and that these two receptors are different transcription factors that likely have distinct roles in estrogen biology.
The amino-terminus of ER␣, but not that of ER␤, functions as an autonomous activating sequence
To determine whether the amino-terminus of ER␤ does, in fact, possess an autonomous activation function, we evaluated the transcriptional activity of the ER␣ and ER␤ N-termini when removed from the context of their intact receptors. Specifically, the N-termini of ER␣ and ER␤ were each fused to the GAL4 transcription factor DBD (Fig. 3A) , and the activity of each construct was compared in transient transfection studies in HepG2, HeLa, MCF-7 (human mammary carcinoma), and SKBR3 (human mammary adenocarcinoma) cells on a GAL4-responsive reporter (Fig. 3, B-E) . The input concentration of each vector used in these studies was that which gave a maximal response under the conditions of the assay. In HepG2 cells, the GAL4-DBD-ER␣ construct possessed more than 18 times the activity of the GAL4 DBD alone, whereas only a 2.4-fold enhancement by the ER␤ construct was observed. In HeLa cells, ER␣ displayed a 5.5-fold increase in transcriptional activity over the control, whereas only a 1.4-fold increase was observed for ER␤. Similarly, in MCF-7 and SKBR3 cells, ER␣ displayed 42-and 53-fold increases in activities, whereas only 3.3-and 6-fold increases were seen for ER␤. These studies illustrate that while the N-terminus of ER␣ has a strong activation domain that functions in a cell-specific manner, the homologous region in ER␤ is much less active. Therefore, it is likely that the repressor function is the primary determinant of the activity of the N-terminus of ER␤ in the whole receptor, and that the distinct transcriptional profiles of the two ERs are mediated in part by differences in their amino-termini.
ER␤ represses ER␣ transcriptional activity at subsaturating concentrations of 17␤-estradiol
Our data indicate that ER␣ and ER␤ are not functionally equivalent and that in many contexts ER␣ is significantly more transcriptionally active than ER␤. Therefore, we considered the possibility that, similar to the effects mediated by PR-A on PR-B activity, ER␤ may act as a transdominant repressor or a modulator of ER␣ activity in contexts where ER␤ is less active. To test this hypothesis, we examined the effect of ER␤ expression on the transcriptional activity of ER␣ when both receptors were expressed in target cells. Specifically, the ER␣ expression vector was transiently transfected into HepG2 cells, either alone or in the presence of increasing amounts of the ER␤ expression vector together with the 3x-ERE-TATA-Luc reporter. The cells were induced with either 100 nm 17␤-estradiol, a saturating concentration at which both receptors demonstrate maximal transcriptional activity, or 100 pm 17␤-estradiol, a subsaturating concentration at which only ER␣ is active. As expected, ER␣ was a better activator of transcription than ER␤ when the assay was performed in the presence of 100 nm 17␤-estradiol. Interestingly, although ER␣ manifests significant ligand-dependent activity, the introduction of increasing amounts of ER␤ into the system had no effect on ER␣ transcriptional activity under the conditions of the assay. However, in the presence of 100 pm 17␤-estradiol, the activity of ER␣ was suppressed by the addition of increasing amounts of the ER␤ expression vector. At equivalent input vector concentrations, the estradiol-stimulated activity of the coexpressed receptors was repressed to 25% of the activity of ER␣ alone. These data strongly support the hypothesis that the pharmacology of estrogen(s) will differ in target cells depending on the relative expression levels of ER␣ and ER␤.
We next compared the activities of ER␣, ER␤, or both receptors together over a full range of estradiol concentrations (Fig. 4B) . Based on the observation that ER␤ functions as a repressor of ER␣ transcriptional activity at low concentrations of hormone, we predicted that the impact of ER␤ on ER␣ would differ at specific hormone concentrations and that the cellular responsiveness to estradiol would be affected by ER␤ expression. Interestingly, we observed that the potency of estradiol in our ER␣-dependent transcription systems was right shifted by 1 log when ER␤ was coexpressed in the system, whereas the efficacy was unaffected. Similar results were also observed when this experiment was re-
The amino-terminus of ER␣, but not that of ER␤, functions as a strong autonomous activating sequence. A, The GAL4-DBD-ER constructs were created by inserting the amino-terminus of each receptor (amino acids 1-182 of ER␣ and 1-95 of ER␤) downstream of the GAL4 transcription factor DBD. B-E, HepG2 cells, HeLa cells, MCF-7 cells, and SKBR3 cells were transiently transfected with the GAL4-DBD or GAL4-ER constructs together with a 5x-GAL4-TATA-Luc reporter (containing five copies of the 17-bp palindromic GAL4 transcription factor response element). Cells were harvested after 48 h and assayed for luciferase activity. All transfections were normalized for efficiency using the internal pCMV-␤-gal control plasmid. The data are presented as fold activation, where 1 represents a measure of the activity of the GAL4-DBD construct alone. Each data point is the average of triplicate determinations.
peated in different cellular contexts (data not shown). From these studies, we conclude that 1) ER␤ is a transdominant repressor of ER␣ transcriptional activity at subsaturating concentrations of estradiol; and 2) ER␤ expression decreases the sensitivity of ER␣-expressing cells to estradiol.
Coexpression of ER␤ suppresses the partial agonist activity of tamoxifen through ER␣
Our observations that the cellular response to estrogen is dependent on the relative expression of ER␣ and ER␤ suggested that the agonist/antagonist activities of mixed agonists such as tamoxifen may be influenced by the relative expression of the two receptors. To determine the impact of coexpression of the two receptor subtypes on tamoxifen pharmacology, the ER␣ and ER␤ expression vectors were transiently transfected into HepG2 cells, either alone or together, and the cellular response to increasing concentrations of 4-hydroxytamoxifen was measured on the C3-Luc reporter (Fig. 5) . As seen before, tamoxifen functioned as an agonist when ER␣ alone was expressed in the cell and showed no agonist activity when ER␤ alone was expressed. In the presence of ER␤, however, the ability of tamoxifen to activate ER␣-mediated transcription was completely suppressed. We noticed that the basal transcription in the pres -FIG. 4 . ER␤ is a transdominant repressor of ER␣ transcriptional activity at subsaturating concentrations of 17␤-estradiol. A, HepG2 cells were transiently transfected with the 3x-ERE-TATA-Luc reporter alone (no ER), the reporter and 250 ng ER␤, or the reporter and 250 ng of the ER␣ expression vector together with increasing concentrations of the ER␤ expression vector (0, 10, 50, and 250 ng). After transfection, cells were treated with vehicle (nh) or 100 nM or 100 pM 17␤-estradiol (E2). After 48 h, cells were harvested and assayed for luciferase activity, and all transfections were normalized for efficiency using the internal pCMV-␤-gal control plasmid. Each data point is the average of triplicate determinations, and the average coefficient of variance for each value is less than 10%. B, HepG2 cells were transiently transfected with either ER␣ or ER␤ expression vectors or equal quantities of both vectors together with the C3-Luc reporter and the pCMV-␤-gal control plasmid. Cells were induced with vehicle (nh) or increasing concentrations (ranging from 1 pM to 1 M) of 17␤-estradiol (E2) for 48 h, and luciferase assays were performed. Each value was normalized to the ␤-galactosidase activity. Each data point is the average of triplicate determinations, and the average coefficient of variance for each value is less than 10%.
ence of both receptors was intermediate between ER␣ and ER␤ alone in this assay. Although we have not pursued this interesting finding further, we do know that all of the basal activity observed in the presence of ER␣ is ER-dependent. Thus, ER␤ may effectively inhibit tamoxifen-dependent ER␣-mediated transcription, but not that activity mediated through the same receptor in the absence of ligand. Overall, these results suggest that the tissue-selective agonist activity of antiestrogens may be determined by the relative expression of ER␣ and ER␤ in a tissue.
ER␣ and ER␤ form heterodimers in vivo
We next investigated the molecular mechanism by which ER␤ modulates ER␣ transcriptional activity. It has recently been reported that coexpression of ER␣ and ER␤ results in the preferential formation of receptor heterodimers (instead of homodimers) that are capable of activating transcription from estrogen-responsive enhancers (20, 21) . Our observation that classical ER␣-and ER␤-mediated responses are modified when the two receptors are coexpressed suggests that these alternative responses could be mediated through receptor heterodimers that may possess unique transcriptional activities. To address this issue we examined the interaction between the two receptors in a mammalian twohybrid assay. HepG2 cells were transfected with the pBKC-DBD-ER␣-LBD(3x) vector and pVP16-ER␤ vectors together with a GAL4-responsive reporter and treated with vehicle or 100 nm 17␤-estradiol (Fig. 6) . The ER␣-LBD(3x) vector con-
FIG. 6. ER␣ and ER␤ form heterodimers in vivo.
HepG2 cells were transiently transfected with either GAL4-DBD or GAL4-ER␣-LBD(3X) (in this construct AF-2 activity is removed to decrease the basal activity, but the dimerization domain is intact) together with either pVP16 or pVP16-ER␤ and the 5x-GAL4-TATA-Luc reporter. Cells were treated with vehicle (nh) or 100 nM 17␤-estradiol (E2) for 48 h, and luciferase assays were performed. Each luciferase value was normalized to the ␤-galactosidase activity. Each data point is the average of triplicate determinations, and the average coefficient of variance for each value is less than 10%.
FIG. 5.
Coexpression of ER␤ suppresses the partial agonist activity of tamoxifen through ER␣. HepG2 cells were transiently transfected with either the ER␣ or ER␤ expression vector or equal quantities of both vectors together with the C3-Luc reporter and the pCMV-␤-gal control plasmid. Cells were induced with vehicle (nh) or increasing concentrations (ranging from 1 pM to 1 M) of 4-hydroxytamoxifen (4OH-T) for 48 h, and luciferase assays were performed. Each value was normalized to the ␤-galactosidase activity. Each data point is the average of triplicate determinations, and the average coefficient of variance for each value is less than 10%.
tains three point mutations in the AF-2 domain that abolish transcriptional activity but have no effect on ER dimerization (11) . We observed that ER␣ and ER␤ show a strong hormonedependent interaction. Furthermore, our results show that ER␣ and ER␤ heterodimerize in vivo and support the recent findings that heterodimers are formed when the two subtypes are coexpressed. Although previous studies have shown that ER␣ and ER␤ heterodimerize in the absence of hormone (20, 21) , these studies were carried out in vitro and may not accurately represent what occurs in the cell where ER␣ and ER␤ do not exist in isolation but, rather, interact with a variety of proteins. Overall, the results imply that the impact of each receptor on the other's pharmacology may be mediated at least in part through the formation of heterodimers with properties that may be different from those of the homodimers.
ER␤ interacts with target gene promoters in the absence of ligand
We have observed that ER␤ suppresses ER␣-mediated transcription at subsaturating levels of hormone. One possible explanation for this activity is that ER␤ may bind its cognate response element in a constitutive manner and thus compete with ER␣ for access to the DNA target. To test this hypothesis, ER␣ and ER␤ were fused to the VP16 activation domain in order to bypass the need for ligand to activate the AFs within the two receptors. Thus, when tethered to DNA, the chimeras will activate transcription regardless of the nature of the bound ligand. HepG2 cells were transiently transfected with increasing concentrations of the pVP16-ER␣ or pVP16-ER␤ expression plasmids together with the 3x-ERE-TATA-Luc reporter in the presence of vehicle or 100 nm 17␤-estradiol. As shown in Fig. 7A , when overexpressed, VP16-ER␣ did have the capacity to interact with DNA in the absence of hormone. However, when VP16-ER␣ was limiting, hormone had a pronounced effect on DNA binding. To eliminate the possibility that the elevated transcriptional responses of VP16-ER␣ in the presence of agonist were due to synergy between the ER␣ activation functions and the VP16 activation domain in the presence of estradiol, we repeated the experiments using VP16-ER␣(3x), which contains three point mutations in the ER␣ AF-2 domain that disrupt the ligand-dependent coactivator binding pocket and nullify the transcriptional activity of the receptor. Under these conditions we observed that hormone was required for DNA binding, even at high receptor concentrations (Fig. 7B) . In contrast to the results obtained with VP16-ER␣, we observed that the ability of VP16-ER␤ to interact with DNA was entirely ligand independent, regardless of the level of expression (Fig. 7C) . These studies reveal another mechanistic difference between ER␣ and ER␤ and suggest that ER␤ regulates ER␣-mediated transcriptional activity at the level of DNA-binding site competition.
Discussion
Differential activities of nuclear hormone receptor subtypes
The ability of two nuclear receptor subtypes to display distinct or even opposing transcriptional activities is an emerging paradigm in nuclear receptor signaling. One example is the human glucocorticoid receptor (GR), which exists in two forms (␣ and ␤) that arise by an alternate splicing event that results in a truncation of the C-terminus in the GR␤ form (22) . Analysis of the transcriptional properties of these two receptors indicated that they both recognize the same intracellular targets, but GR␤ is unable to bind agonists (22) . Therefore, although GR␣ can enhance the transcription of glucocorticoid-responsive enhancers, GR␤ is not transcriptionally active and can act as a dominant negative inhibitor of GR␣ activity. The contrasting activities of the GRs suggest that the relative tissue distributions of the two receptors are a major determinant of the biological effects of glucocorticoid compounds. The existence of two forms of the human PR, each with different biological activity, extends the concept that receptor isoforms are an important part of steroid hormone receptor pharmacology. The two PRs are identical in sequence, with the exception that hPR-B has an additional 164 amino acids within its N-terminus originating from an alternate translation initiation event. These isoforms have been shown to bind the same ligands and regulate transcription of the same genes. However, in most cell types PR-B is a transcriptional activator, whereas PR-A acts as a transdominant repressor of PR-B. Interestingly, in the presence of an activating ligand, human PR-A can inhibit the transcriptional activities of ER, GR, androgen receptor, and mineralocorticoid receptor (15) .
Our studies suggest that the human ER␣ and ER␤ provide yet another example of two nuclear receptor subtypes that demonstrate distinct transcriptional activities. As is seen with human PRs, the differential activities of the two ERs arise from functional variations in the receptor N-termini. ER␣ contains a constitutive AF-1 in the N-terminus that functions in a cell-and promoter-specific manner to enhance the overall transcriptional response of the receptor. However, the corresponding region of ER␤ lacks significant transcriptional activity and contains a repressor domain that decreases the overall transcriptional activity of the receptor. This inhibitory region functions only in the context of the intact receptor, as has been shown for the inhibitory Nterminus of PR-A (15) and for the repressor domains of the transcription factor c-Fos (23) . Our studies do not eliminate the possibility that ER␤ does, in fact, have an AF-1, but suggest that its function is masked by the presence of an amino-terminal repressor domain. This hypothesis is supported by the fact that the N-terminus of ER␤ showed low levels of autonomous transcriptional activity when fused to the heterologous GAL4-DBD. Furthermore, recent studies have shown that ER␤ transcriptional activity can be stimulated by the mitogen-activated protein kinase pathway (23a), and that this activity appears to require an intact ER␤ aminoterminus. Mutational analysis will be required to determine whether ER␤ contains separate activation and repression domains within its amino-terminus.
An additionally important distinction between ER␣ and ER␤ resulted from our finding that ER␣-AF-1 and AF-2 act synergistically under most circumstances, whereas the AF-2 of ER␤ functions as an independent activation domain. It is likely, therefore, that ER␣ and ER␤ will display differences in their preferences for coactivators and corepressors in target cells. In recent years, several transcriptional coactivator proteins have been identified that interact with the hormonebinding domain of nuclear receptors and are thought to mediate the activity of AF-2. Specifically, the coactivators steroid receptor coactivator-1 (SRC-D), amplified in breast cancer (AIB1), transcriptional intermediary factor-2 (TIF-2), and glucocorticoid receptor interacting protein (GRIP-1) (murine homolog of TIF-2) and the cointegrator CBP/p300 have been shown to potentiate the activity of ER␣ and other nuclear receptors (24 -27) . The C-termini of both ER␣ and ER␤ have been shown to bind the coactivators SRC-1 and GRIP-1 in an agonist-dependent manner (28, 29) (our unpublished results). Therefore, it is possible that although the cofactors that mediate transcriptional activity of the two ERs are the same, these proteins may interact with distinct regions of each receptor or differentially recruit other cellular factors when bound to one receptor vs. the other. Although sequence comparisons suggest that the N-terminus may be the primary discriminator by which coactivators can interact with the receptors, the fact that AF-2 of ER␣ and ER␤ are also functionally different suggests that the process is much more complex. It is not clear at this time whether AF-1 and/or AF-2 interact with distinct coactivators or if these domains have independent contact sites on the same coactivator. Regardless, it is clear that in the context of ER␣, AF-1 is required for maximal agonist-induced transcriptional activity, as mutations in this domain have been shown to abolish tamoxifen partial agonist activity and dampen the response to estrogen (30) . The absence of an efficient AF-1 in ER␤ clearly influences the manner in which coactivators interface with this receptor and ultimately its ligand responsiveness. Our data are also compatible with the concept that the N-terminus of ER␤ binds a protein that has an autonomous inhibitory ac- FIG. 7 . ER␤ interacts with target gene promoters in the absence of ligand. HepG2 cells were transiently transfected with increasing concentrations of the pVP16-ER␣ expression vector (A), the pVP16-ER␣(3x) expression vector (B), or the pVP16-ER␤ expression vector (C). Each expression construct includes the VP16 activation domain sequence fused 5Ј to the entire coding sequence for the human ER␣, ER␣(3x) mutant, or ER␤. After transfection, cells were treated with vehicle (nh) or 100 nM 17␤-estradiol (E2) for 48 h, and luciferase assays were performed. Each value was normalized to the ␤-galactosidase activity. Each data point is the average of triplicate determinations, and the average coefficient of variance for each value is less than 10%. tivity or one that inhibits transcriptional activity by blocking the binding of coactivators to AF-1 and AF-2. If this is the case, then it is possible that in tissues in which the putative repressor protein is absent, antiestrogens could manifest partial agonist activity, and agonists would be more potent receptor activators.
Roles of ER␣ and ER␤ in determining cellular sensitivity to estrogen
One of the most important findings of this study is that the relative levels of ER␣ and ER␤ are an important determinant of cellular sensitivity to estrogens. Although ER␣ is the stronger transcriptional activator of the two ER isoforms, at physiological concentrations of estradiol, coexpression of ER␤ results in suppression of both the efficacy and the potency of hormone-stimulated responses. This suggests that it will be important to determine the extent to which the two receptors colocalize in order to more accurately predict the biological responses to ER agonists in specific target tissues. The ability of ER␤ to function as a transcriptional inhibitor or activator, depending on the agonist concentration, suggests that completely different patterns of gene expression may be observed at different hormone levels. In addition, the ability of ER␤ to switch from a transcriptional repressor to an activator as estradiol levels rise may provide cells expressing both isoforms with a mechanism to control cellular sensitivity to hormones. Such a process could explain why during the early part of the menstrual cycle, low plasma concentrations of estradiol exhibit an inhibitory effect on gonadotropin secretion, whereas when levels of hormone are elevated during the late follicular phase, the pituitary release of LH and GnRH secretion from the hypothalamus is enhanced. In light of the recent localization of ER␤ to rat hypothalamic neurons projecting to the pituitary (31, 32) , it is possible that the balance between ER␣ and ER␤ activities in these tissues may mediate the differential sensitivities to estrogens throughout the menstrual cycle. The role of ER␤ in the regulation of cellular responsiveness to agonists may merit consideration in dosing regimens of estrogen-like pharmaceutical compounds, as it is likely that fluctuations in the bioavailability of receptor activating ligands may have a greater impact in tissues where ER␣ and ER␤ colocalize. This may be particularly important in ER-positive breast tumors, where it has been shown that ER␤, in addition to ER␣, may be expressed (33) .
Our studies also suggest that the relative levels of ER␣ and ER␤ are an important determinant of the pharmacology of antiestrogens. The observation that tamoxifen is a more potent competitive antagonist of ER␤ (8) and does not display agonist activity on the receptor raises the possibility that there will be a better response to tamoxifen in ER␤-positive tumors. In view of our finding that ER␤ suppresses the partial agonist activity of tamoxifen on ER␣, it will be interesting to determine whether tumors expressing both subtypes show a better response to tamoxifen as well. It will also be important to determine whether ER␤ is down-regulated in tamoxifen-resistant tumors as an adaptive mechanism for growth.
A working model to explain the cross-talk between ER␣ and ER␤
We have developed a working model to explain how ER␤ can regulate ER␣ transcriptional activity in cells where the receptors are coexpressed. This model is based on two fundamental observations: 1) ER␤ binds to target gene promoters in a ligand-independent manner; and 2) ER␤ can form heterodimers with ER␣ within cells. Thus, in the presence of low subsaturating concentrations of hormone, inactive ER␤ binds to its target response element and competitively blocks ER␣ binding. As hormone levels rise, the amount of activated ER␣ and ER␤ also rises, sufficient activated receptor is formed to compete with the unliganded, inactive ER␤, and transcription can proceed. A purely competitive interaction would predict that as ER␤ levels rise, agonist efficacy would decrease to a level approaching that observed when ER␤ alone is expressed in cells. However, the observation that under conditions of hormone excess, overexpression of ER␤ does not decrease the efficacy of estradiol suggests that the interaction of ER␣ and ER␤ is more complex. We believe that under hormone-saturating conditions, ER␣ and ER␤ can form heterodimers and that the transcriptional activity of the heterodimer is indistinguishable from that of the ER␣ homodimer. Although difficult to address experimentally, it is possible that of the three potential ER complexes, the ER␤ homodimer has the highest affinity for corepressors and/or the lowest affinity for coactivators, and consequently, it is the least transcriptionally active. However, in the context of a heterodimer, the presence of ER␣ assists ER␤ in recruiting cofactors such as SRC-1 and GRIP-1. Thus, the resultant complex of ER␣/ER␤ and their associated coactivators is indistinguishable from that formed by an ER␣ homodimer. If this latter model is found to be true, then we would predict that the major role of ER␤ is to modulate ER␣ transcriptional activity at low hormone levels.
